Towards evidence-based genomic medicine: filling the evidence gaps through modelling studies GENOMICMEDICINE (WC 2014-033)


Starting date: 01/01/2014


At increasingly high rate, genome-wide association and whole genome sequencing studies unravel genetic variants implicated in common diseases such as coronary heart disease, cancer, dementia and type 2 diabetes. One of the major promises is that these advances will lead to more personalized medicine, in which preventive and therapeutic interventions are targeted to individuals based on their genetic profiles. Identifying the promising genomic applications and translating the new emerging genomic knowledge into public health and medical care are two of the major challenges for the next decades.
There is increasing interest in the early adoption of novel applications and many commercial applications are already marketed without supporting empirical evidence. Already now, regulatory agencies like the US Food and Drug Administration face substantial gaps in empirical evidence, which hamper proper recommendations. The increasing interest in genomic medicine, the evidence gaps and the scarcity of research budgets are strong incentives to search for novel strategies that make the process of translation research more efficient and effective.